GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Total Assets

NurExone Biologic (FRA:J90) Total Assets : €3.26 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Total Assets?

NurExone Biologic's Total Assets for the quarter that ended in Sep. 2024 was €3.26 Mil.

During the past 12 months, NurExone Biologic's average Total Assets Growth Rate was 308.30% per year.

Total Assets is connected with ROA %. NurExone Biologic's annualized ROA % for the quarter that ended in Sep. 2024 was -142.67%. Total Assets is also linked to Revenue through Asset Turnover. NurExone Biologic's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.


NurExone Biologic Total Assets Historical Data

The historical data trend for NurExone Biologic's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Total Assets Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
Total Assets
2.51 2.64 1.99

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 1.99 3.81 3.06 3.26

NurExone Biologic Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

NurExone Biologic's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=0.173+1.817
=1.99

NurExone Biologic's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=2.638+0.618
=3.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NurExone Biologic  (FRA:J90) Total Assets Explanation

Total Assets is connected with ROA %.

NurExone Biologic's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-4.504/( (3.058+3.256)/ 2 )
=-4.504/3.157
=-142.67 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

NurExone Biologic's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (3.058+3.256)/ 2 )
=0/3.157
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

NurExone Biologic Total Assets Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines